Current state · 2026.
The current BE stack is broadly converged around ICH M9 biowaiver thinking and the familiar 80–125% BE acceptance frame, while operational divergence remains in highly variable products, NTI handling, reference-product sourcing, and country-specific evidence expectations.
Current state · 2026.
Live now · in transitionThe current BE stack is broadly converged around ICH M9 biowaiver thinking and the familiar 80–125% BE acceptance frame, while operational divergence remains in highly variable products, NTI handling, reference-product sourcing, and country-specific evidence expectations. What is live, what needs verification:
Standard BE bound broadly converged.
For many conventional PK BE studies, 80.00–125.00% using a 90% confidence interval for log-transformed exposure metrics remains the familiar default frame across major source families. Exact applicability depends on product type, metric, design, and jurisdiction-specific guidance.
HV drug scaling divergence.
Highly variable-product approaches remain jurisdiction-specific. FDA product-specific recommendations may allow reference-scaled approaches; EMA generally applies scaling more narrowly and keeps AUC within the standard frame. Parallel filings should be checked against each region's current product-specific expectations.
NTI drug lists divergent.
Narrow therapeutic index handling remains jurisdiction-specific. Sponsors should verify current lists, product-specific recommendations, and tightened-design expectations rather than assuming one global NTI rule.
BCS biowaiver convergence.
ICH M9 supports convergence for eligible Class I and selected Class III biowaivers, but excipient, dissolution, product, and jurisdiction-specific conditions still control eligibility. Class II/IV assumptions require specific justification and current guidance review.
Reference product sourcing.
Reference-product sourcing remains jurisdiction-specific. FDA, EMA, Brazil, and WHO pathways have different comparator expectations, bridging routes, and documentation needs; teams should verify current comparator lists before protocol lock.
Biosimilar PK BE distinct.
Same TOST machinery (80–125%) but a totality-of-evidence framework: analytical similarity → PK similarity → comparative efficacy. Immunogenicity (ADA assays) in parallel. Distinct rules in FDA 351(k), EMA biosimilar guideline, ANVISA RDC 55/2010.
Biosimilar interchangeability.
Interchangeability remains jurisdiction-specific. FDA has a formal interchangeable pathway; EU use decisions have historically involved member-state practice and scientific/regulatory statements; Brazil-specific status should be verified against current ANVISA sources before public or filing claims.
Brazil-specific BE operations need source check.
Brazil-facing BE work may require additional operational controls around comparator sourcing, volunteer management, CRO/site expectations, and documentation. These details should be verified against the current ANVISA source stack before study design.
Virtual BE / PBPK trajectory.
Model-informed evidence can support selected development questions and regulatory discussions, but use as a primary replacement for in vivo BE remains product- and agency-specific. Treat PBPK/MIDD as a watch area unless a current product-specific source says otherwise.
Global 2026 stack.
For multi-region work, design conservatively, verify current product-specific expectations, and preserve evidence for reference-product sourcing, study design rationale, bioanalysis, statistics, and jurisdiction-specific requirements.
Official source register.
Regulator / ICH anchorsICH M13A bioequivalence guideline.
Official FDA-hosted page for ICH M13A on bioequivalence for immediate-release solid oral dosage forms. Use as the first harmonised anchor for conventional oral IR BE framing.
BCS-based biowaiver guidance.
Official ICH M9 Step 4 guideline. Use for BCS classification, solubility/permeability thinking, and eligible biowaiver conditions.
Bioanalytical method validation and study sample analysis.
Official ICH M10 Step 4 guideline. Use for the bioanalytical evidence layer that supports BA/BE concentration data.
Product-specific guidances for generic development.
FDA product-specific guidance collection. Use before protocol lock because product-level recommendations can change design, fed/fasted, analyte, and BE expectations.
US bioavailability and bioequivalence regulation.
Electronic Code of Federal Regulations anchor for US BA/BE definitions and requirements. Use for statutory/regulatory context, not as a complete study-design manual.
Guideline on the investigation of bioequivalence.
EMA scientific guideline landing page for BE investigation. Use for EU framing, while checking product-specific or updated procedural context where relevant.
Multisource generic products and interchangeability.
WHO IRIS record for multisource pharmaceutical product guidance. Use as a WHO anchor for generic interchangeability and BE expectations in broader access settings.